Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.

Summary

The purpose of this study was to assess the efficacy and safety of secukinumab in Chinese participants with active Psoriatic arthritis (PsA ) compared to placebo.

Timeline

Start

2021-06-24

Primary completion

2022-06-02

Completion

2023-03-10

Outcome

Met primary endpoint

registry analysis (other test); Secukinumab 150 mg (Group 1) vs Placebo of Study Drug (Group 2); Marginal difference 39.91 (95% CI 10.87 to 68.95); Regression, Logistic NCT04711902 ↗

Drugs

Indications